BTIG Research Has Lowered Expectations for Ovid Therapeutics (NASDAQ:OVID) Stock Price
Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. A number of other research firms also recently issued reports on OVID. Oppenheimer raised shares of Ovid Therapeutics […]
Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. A number of other research firms also recently issued reports on OVID. Oppenheimer raised shares of Ovid Therapeutics […]
